Top Tweets for #STMN2
QurAlis' #STATHMIN-2 (#STMN2) program - QRL-201 - is featured in a recent blog by @TargetALS_fdn that shares insights into advancements in #ALS drug discovery and development. The blog highlights the 'cutting-edge research funded by Target ALS and its significant impact on the current and future clinical trial landscape.' QRL-201 is a first-in-class #precisionmedicine product candidate that aims to restore STMN2 expression in ALS patients. QRL-201 is being evaluated in the Phase I ANQUR clinical trial - the first-ever study to evaluate a potential therapy to rescue STMN2 expression in ALS patients. #neurodegenerativediseases #neurologicaldiseases https://t.co/EmwnrzInps
QurAlis presents! Emma Bowden, PhD, QurAlis' head of development, recently presented an overview of our Phase 1 ANQUR clinical trial - the first-ever study to evaluate a therapy that rescues #STATHMIN-2 (#STMN2) in #ALS - at the 3rd ALS Drug Development Summit. ANQUR is evaluating QRL-201, a first-in-class STMN2 #precisionmedicine for ALS that rescues STMN2 expression in ALS patients and could halt disease progression. QurAlis is exploring the use of the https://t.co/TspCEN7Cdw Digital Twin Generators in ANQUR. #neurodegenerativediseases
QurAlis presents! QurAlis' head of development Emma Bowden, PhD, will present an overview of our Phase 1 ANQUR clinical trial evaluating QRL-201 at the 3rd ALS Drug Development Summit. QRL-201 is a first-in-class #STATHMIN-2 (#STMN2) #precisionmedicine for #ALS. ANQUR is the first-ever study to evaluate a therapy that rescues STMN2 expression in ALS patients and could halt disease progression. STMN2 is a well-validated protein important for neural repair and axonal stability, the expression of which is significantly decreased in nearly all ALS patients. QurAlis is exploring the use of the https://t.co/TspCEN7Cdw Digital Twin Generators in ANQUR with the goal of supporting both ANQUR and future studies for QRL-201. #neurodegenerativediseases https://t.co/z4pu4FRjN4
QurAlis is honored to sponsor the @TargetALS 2024 Annual Meeting being held this week to accelerate progress toward the development of new therapeutic approaches for #ALS. Emma Bowden, PhD, QurAlis' head of development, was a featured speaker and presented an update on our #STMN2 program in ALS. #precisionmedicine #neurodegenerativediseases https://t.co/0VtNtmghv9
Check it out! QurAlis' lead #ALS programs targeting #STMN2 and #UNC13A are described in #CellTrendsinMolecularMedicine review paper, 'The sense of antisense therapies in ALS.' #precisionmedicine #neurodegenerativediseases #TDP43 #ASO https://t.co/lBK6y1DVR9
Congratulations to #TargetALS on their 10-year anniversary! QurAlis is grateful for TargetALS' support of the foundational work on our #Kv7 and #biomarkers in #STMN2 programs. #precisionmedicine #neurodegenerativediseases #tenyearstals
Congrats to Drs. Lutz et al for their research that further confirms and details the role of #STMN2 in #ALS. This provides further evidence validating our pioneering approach in developing #precisionmedicines for ALS and other #neurodegenerativediseases. https://t.co/qDubnjRWUw
QurAlis at #PACTALS23! VP, ClinOps @KristinaJohnson (l) & assoc. dir., ClinOps @SamanthaRubino (r) presented on our QRL-201 ANQUR clinical trial - 1st-ever study to evaluate a therapy that rescues #STMN2 expression in #ALS patients. #precisionmedicine #neurodegenerativediseases
QurAlis at #ENCALS23! Clinical team members @KristianaSalmon and @ClaridaMartinez presented a poster on our QRL-201 ANQUR clinical trial - the 1st-ever study to evaluate a therapy that rescues #STMN2 expression in #ALS patients. #precisionmedicine #neurodegenerativediseases
QurAlis is excited to announce UK MHRA granted CTA authorisation for QRL-201, marking the 3rd regulatory clearance for our ANQUR study - the 1st-ever clinical trial to evaluate a therapy that rescues #STMN2 expression in #ALS patients. #precisionmedicine https://t.co/aq7ut2XVd4
Excited to receive EU CTA for our Phase 1 ANQUR clinical trial of QRL-201, a 1st-in-class #STMN2 #precisionmedicine for #ALS. This marks the 2nd regulatory clearance for ANQUR, which we expect to initiate in the EU by 4Q23. #neurodegenerativediseases https://t.co/BWCEHMv7mM
#ALS 治療標的を特定した？UCSDScience報告に注目。#TDP43タンパク異常 が駆動するのは、#STMN2 RNAの #異様スプライシング。 そのレベルを回復させる #RNA標的化CRISPReffectors ・ #ASOs を開発した、マウスを治療中、と。
https://t.co/7xhUQP9lkt
Check it out! Our two lead #ALS programs targeting #STMN2 and #Kv7 are described in #NatureReviewsDrugDiscovery #precisionmedicine #neurodegenerativediseases #TDP43 https://t.co/LLzOnb1O4H
Thrilled that Health Canada authorized our CTA for QRL-201, a first-in-class #STMN2 #ALS #precisionmedicine. It'll be the first ever clinical trial to evaluate a therapy that rescues STMN2 expression. This is a major milestone! #neurodegenerativediseases https://t.co/QPOJO3Kdo8
Facing delays in your research due to limited Stathmin-2 antibody availability or long lead times? Fear not, because Proteintech’s STMN2 antibodies are in stock and available for next day delivery!
https://t.co/Ape4Vt1zct
#neurodegeneration #stmn2 #tdp43 #als
Congratulations to @KelseyKrus & colleagues from the DiAntonio & Milbrandt labs demonstrating that loss of STMN2 is likely an important contributor to ALS pathology https://t.co/Ltp2r5rjW5 #ALS #TDP43 #STMN2 #MND @ALSCenterWashU @HopeCenterWUSTL @WashUDevBio @WUSTLmstp
Faze neuroscientist Joseph Kilm, PhD, co-authored a manuscript recently published in @NeuroCellPress exploring the TDP43-regulated gene #STMN2 and the potential connection between TDP43 dysfunction & motor #neuropathy as observed in #ALS. Read: https://t.co/kOngE4RHMF
Encouraged to see additional research about the importance of #STMN2 in #ALS, validating our approach. #precisionmedicine #neurodegenerativediseases https://t.co/fvcMl6FH87
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
240.8M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
111.2M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.8M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91M followers
KATY PERRY
@katyperry
88M followers
Taylor Swift
@taylorswift13
81.9M followers
Lady Gaga
@ladygaga
73.4M followers
Virat Kohli
@imvkohli
70.4M followers
Kim Kardashian
@kimkardashian
69.9M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.1M followers
Neymar Jr
@neymarjr
63.2M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
61.1M followers
X
@x
60.8M followers